Literature DB >> 24125459

Association between metabolic syndrome and rate of lung function decline: a longitudinal analysis.

H-K Koo1, D K Kim, H S Chung, C-H Lee.   

Abstract

SETTING: Factors that influence the annual rate of decline of lung function need to be verified.
OBJECTIVE: To determine the effects of metabolic syndrome, especially hypertension, on the annual rate of decline in lung function.
DESIGN: A total of 635 healthy participants without known respiratory disease completed baseline and follow-up routine check-ups, including a pulmonary function test, for at least 3 years. Age, sex, height, weight, waist circumference, smoking status, other underlying diseases, and pulmonary function and blood test results were carefully reviewed.
RESULTS: In a multivariable analysis of baseline data, diabetes was associated with lower forced vital capacity (FVC). In longitudinal analysis using mixed linear regression, hypertension was an independent predictor for acceleration of FVC decline rate compared to subjects without hypertension (-37.2 vs. -18.5 ml/year), while anti-hypertensive medication decelerated FVC decline in hypertensive subjects (-58.9 vs. -32.3 ml/year). The annual rate of decline in forced expiratory volume in 1 second (FEV1) in groups with and without hypertension did not differ significantly. No significant difference was found in FEV1 or FVC annual rates of decline with regard to the presence of diabetes, dyslipidaemia, obesity or abdominal obesity.
CONCLUSION: Hypertension is associated with an accelerated decline in FVC, but anti-hypertensive medication might abate the rate of decline in asymptomatic healthy subjects.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24125459     DOI: 10.5588/ijtld.12.0906

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  7 in total

1.  Loss of Lung Health from Young Adulthood and Cardiac Phenotypes in Middle Age.

Authors:  Michael J Cuttica; Laura A Colangelo; Sanjiv J Shah; Joao Lima; Satoru Kishi; Alexander Arynchyn; David R Jacobs; Bharat Thyagarajan; Kiang Liu; Donald Lloyd-Jones; Ravi Kalhan
Journal:  Am J Respir Crit Care Med       Date:  2015-07-01       Impact factor: 30.528

2.  Restrictive pattern on spirometry: association with cardiovascular risk and level of physical activity in asymptomatic adults.

Authors:  Evandro Fornias Sperandio; Rodolfo Leite Arantes; Agatha Caveda Matheus; Rodrigo Pereira da Silva; Vinícius Tonon Lauria; Marcello Romiti; Antônio Ricardo de Toledo Gagliardi; Victor Zuniga Dourado
Journal:  J Bras Pneumol       Date:  2016 Jan-Feb       Impact factor: 2.624

3.  Decline in lung function rather than baseline lung function is associated with the development of metabolic syndrome: A six-year longitudinal study.

Authors:  Soo Kyoung Kim; Ji Cheol Bae; Jong-Ha Baek; Jae Hwan Jee; Kyu Yeon Hur; Moon-Kyu Lee; Jae Hyeon Kim
Journal:  PLoS One       Date:  2017-03-27       Impact factor: 3.240

4.  The relationship between metabolic syndrome and asthma in the elderly.

Authors:  Sangshin Park; Nam-Kyong Choi; Seungsoo Kim; Chang-Hoon Lee
Journal:  Sci Rep       Date:  2018-06-20       Impact factor: 4.379

5.  An Elevated METS-IR Index Is Associated With Higher Asthma Morbidity and Earlier Age of First Asthma in US Adults: Results Based on a Cross-Sectional Study.

Authors:  Yan Chen; Junping Yang; Kexing Han; Yan Wang; Cuixia Zhuang; Laxiang Zhu; Mingwei Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-11       Impact factor: 6.055

6.  Influence of cardiovascular risk burden on pulmonary function trajectory: role of physical and social activities.

Authors:  Yang Bai; Jiao Wang; Ruixue Song; Zhangyu Wang; Xiuying Qi; Aron S Buchman; David A Bennett; Weili Xu
Journal:  Aging (Albany NY)       Date:  2022-08-04       Impact factor: 5.955

7.  Prevalence and Predictors of Metabolic Syndrome among Patients with Bronchial Asthma: A Cross Sectional Study.

Authors:  Abdellah H K Ali
Journal:  Open Respir Med J       Date:  2021-06-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.